PIM
PTCT icon

Partner Investment Management’s PTC Therapeutics PTCT Stock Holding History

Partner Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-9,900
Closed -$30K – 82
2015
Q3 		$30K Buy
+9,900
New +$423K 0.05% 63

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Partner Investment Management's PTCT Position: Q4 2019 in Review

Partner Investment Management sold out of PTC Therapeutics (PTCT) in Q4 2019, closing a stake of 20,028 shares — an estimated $677K sold.

Partner Investment Management first reported a position in PTCT in Q4 2014 and held it in 5 quarters. The position peaked at $677K in Q3 2019. 206 funds tracked by Wall St. Rank hold PTCT as of Q4 2019.

  • Partner Investment Management reported no remaining PTC Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Partner Investment Management sold 20,028 PTC Therapeutics shares in Q4 2019, an estimated $677K.
  • Partner Investment Management first reported a position in PTC Therapeutics in Q4 2014 and held it in 5 quarters.
  • Partner Investment Management's PTC Therapeutics position peaked at $677K in Q3 2019.
  • 206 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2019.

Based on Partner Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.